Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination.
Forensic Sci Med Pathol
; 18(1): 74-79, 2022 03.
Article
em En
| MEDLINE
| ID: mdl-34735684
This report describes the clinical context and autopsy findings in the first reported fatal case of acute disseminated encephalomyelitis (ADEM), developed after being vaccinated using the Oxford/AstraZeneca COVID-19 vaccine. ADEM is a rare autoimmune disease, causing demyelination in the brain and spinal cord. A wide variety of precipitating factors can trigger ADEM, and it has long been known to be a rare adverse event following some types of vaccinations. Recently, ADEM has also been associated with COVID-19 infection and (very rarely) with COVID-19 vaccination. The reports of the latter however all pertain to living patients. Our case demonstrates that ADEM should be considered in patients developing neurological symptoms post COVID-19 vaccination, although that this adverse reaction is likely to remain extremely rare. Our report further emphasizes the added value of comprehensive post mortem investigation to confirm ante mortem diagnosis and to determine vaccination safety.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Encefalomielite Aguda Disseminada
/
COVID-19
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Forensic Sci Med Pathol
Assunto da revista:
JURISPRUDENCIA
/
MEDICINA
/
PATOLOGIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Austrália